NASDAQ:MEDP Medpace Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Medpace Holdings Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $111.38 +1.47 (+1.34 %) (As of 09/29/2020 12:00 AM ET) Add Compare Share Today's Range$109.90Now: $111.38▼$112.0450-Day Range$106.94MA: $120.79▼$130.6152-Week Range$58.72Now: $111.38▼$144.49Volume261,180 shsAverage Volume342,108 shsMarket Capitalization$3.94 billionP/E Ratio39.64Dividend YieldN/ABeta1.3 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Medpace Holdings, Inc., a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas. Its drug development services include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is headquartered in Cincinnati, Ohio.Read More Beat the Market (BTM) Rank™ 1.2 Analyst's Opinion Consensus RatingMedpace has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $97.67, Medpace has a forecasted downside of 12.3% from its current price of $111.38.Amount of Analyst CoverageMedpace has only been the subject of 2 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesMedpace has received 293 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMedpace has received 308 “underperform” votes. (Add your “underperform” vote.)Community SentimentMedpace has received 51.25% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Medpace and other stocks. Vote “Outperform” if you believe MEDP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MEDP will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMedpace does not currently pay a dividend.Dividend GrowthMedpace does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Medpace insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $131,404,033.00 in company stock.Percentage Held by InsidersOnly 26.00% of the stock of Medpace is held by insiders.Percentage Held by Institutions79.51% of the stock of Medpace is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Medpace are expected to grow by 10.94% in the coming year, from $3.93 to $4.36 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Medpace is 39.64, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 18.56.Price to Earnings Ratio vs. SectorThe P/E ratio of Medpace is 39.64, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.08.Price to Book Value per Share RatioMedpace has a P/B Ratio of 5.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.2Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.05 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Commercial physical research Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MEDP Previous Symbol CUSIPN/A CIK1668397 Webwww.medpace.com Phone513-579-9911Debt Debt-to-Equity RatioN/A Current Ratio0.94 Quick Ratio0.94Price-To-Earnings Trailing P/E Ratio39.64 Forward P/E Ratio28.34 P/E GrowthN/A Sales & Book Value Annual Sales$860.97 million Price / Sales4.58 Cash Flow$3.56 per share Price / Cash Flow31.32 Book Value$20.16 per share Price / Book5.52Profitability EPS (Most Recent Fiscal Year)$3.02 Net Income$100.44 million Net Margins12.11% Return on Equity16.05% Return on Assets10.08%Miscellaneous Employees3,500 Outstanding Shares35,408,000Market Cap$3.94 billion Next Earnings Date10/26/2020 (Confirmed) OptionableOptionable $111.38 +1.47 (+1.34 %) (As of 09/29/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive MEDP News and Ratings via Email Sign-up to receive the latest news and ratings for MEDP and its competitors with MarketBeat's FREE daily newsletter. Medpace (NASDAQ:MEDP) Frequently Asked Questions How has Medpace's stock been impacted by Coronavirus (COVID-19)? Medpace's stock was trading at $83.64 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MEDP shares have increased by 33.2% and is now trading at $111.38. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Medpace? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Medpace. When is Medpace's next earnings date? Medpace is scheduled to release its next quarterly earnings announcement on Monday, October 26th 2020. View our earnings forecast for Medpace. How can I listen to Medpace's earnings call? Medpace will be holding an earnings conference call on Monday, October 26th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available. How were Medpace's earnings last quarter? Medpace Holdings Inc (NASDAQ:MEDP) issued its earnings results on Monday, July, 27th. The company reported $0.68 EPS for the quarter, topping the Zacks' consensus estimate of $0.40 by $0.28. The firm had revenue of $205 million for the quarter, compared to analysts' expectations of $181.17 million. Medpace had a net margin of 12.11% and a return on equity of 16.05%. Medpace's revenue was down 4.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.81 earnings per share. View Medpace's earnings history. What guidance has Medpace issued on next quarter's earnings? Medpace updated its FY20 earnings guidance on Monday, July, 27th. The company provided earnings per share guidance of $3.62-3.83 for the period, compared to the Thomson Reuters consensus estimate of $2.33. The company issued revenue guidance of $880-920 million, compared to the consensus revenue estimate of $831.87 million. What price target have analysts set for MEDP? 5 Wall Street analysts have issued 12 month price objectives for Medpace's shares. Their forecasts range from $75.00 to $124.00. On average, they anticipate Medpace's stock price to reach $97.67 in the next year. This suggests that the stock has a possible downside of 12.3%. View analysts' price targets for Medpace. Are investors shorting Medpace? Medpace saw a decline in short interest in the month of September. As of September 15th, there was short interest totaling 1,230,000 shares, a decline of 11.5% from the August 31st total of 1,390,000 shares. Based on an average trading volume of 407,400 shares, the short-interest ratio is presently 3.0 days. Currently, 4.5% of the shares of the company are sold short. View Medpace's Short Interest. Who are some of Medpace's key competitors? Some companies that are related to Medpace include EXACT Sciences (EXAS), PPD (PPD), Charles River Laboratories Intl. (CRL), Icon (ICLR), Exelixis (EXEL), PRA Health Sciences (PRAH), Syneos Health (SYNH), BTG (BTGGF), National Research (NRC), Precigen (PGEN), STARPHARMA HOLD/S (SPHRY), Anavex Life Sciences (AVXL), Luna Innovations (LUNA), Pieris Pharmaceuticals (PIRS) and Eloxx Pharmaceuticals (ELOX). View all competitors. What other stocks do shareholders of Medpace own? Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), EXACT Sciences (EXAS), JD.Com (JD), Square (SQ), Baidu (BIDU), Alibaba Group (BABA), Bilibili (BILI), Advanced Micro Devices (AMD), Intuitive Surgical (ISRG) and Alteryx (AYX). Who are Medpace's key executives? Medpace's management team includes the following people: Dr. August James Troendle, Chairman, Pres & CEO (Age 63)Mr. Jesse J. Geiger, CFO & Chief Operating Officer of Laboratory Operations (Age 45)Ms. Susan E. Burwig, Exec. VP of Operations (Age 56)Mr. Stephen P. Ewald, Gen. Counsel & Corp. Sec. (Age 50)Mr. Todd Meyers, VP of Bus. Devel. & Marketing When did Medpace IPO? (MEDP) raised $150 million in an IPO on Thursday, August 11th 2016. The company issued 7,000,000 shares at $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers. What is Medpace's stock symbol? Medpace trades on the NASDAQ under the ticker symbol "MEDP." How do I buy shares of Medpace? Shares of MEDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Medpace's stock price today? One share of MEDP stock can currently be purchased for approximately $111.38. How big of a company is Medpace? Medpace has a market capitalization of $3.94 billion and generates $860.97 million in revenue each year. The company earns $100.44 million in net income (profit) each year or $3.02 on an earnings per share basis. Medpace employs 3,500 workers across the globe. What is Medpace's official website? The official website for Medpace is www.medpace.com. How can I contact Medpace? Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company can be reached via phone at 513-579-9911 or via email at [email protected] This page was last updated on 9/29/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
